6 completed, 1 active not recruiting, 1 available, 1 recruiting. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 5, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow plozasiran: new trials by email Literature Review of plozasiran trials Research Report on plozasiran
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis Plozasiran, Placebo - Severe Hypertriglyceridemia | Phase 3 | Recruiting | Arrowhead Pharmaceuticals | 288 | 2025-04-24 | 2026-09-21 |
| Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia Plozasiran Injection - Hypertriglyceridemia | Phase 3 | Active not recruiting | Arrowhead Pharmaceuticals | 710 | 2025-04-09 | 2026-10-01 |
| Study of Plozasiran in Adults With Severe Hypertriglyceridemia Plozasiran Injection, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Arrowhead Pharmaceuticals | 311 | 2024-07-23 | 2026-10-09 |
| Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia Plozasiran Injection, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Arrowhead Pharmaceuticals | 446 | 2024-07-22 | 2026-10-08 |
| Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia Plozasiran Injection, Placebo - Hypertriglyceridemia | Phase 3 | Completed | Arrowhead Pharmaceuticals | 1456 | 2024-05-21 | 2026-09-25 |
| A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome Plozasiran, Placebon - Familial Chylomicronemia Syndrome | Phase 3 | Completed | Visirna Therapeutics HK Limited | 37 | 2023-07-10 | 2026-02-27 |
| Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) Plozasiran, Placebo - Familial Chylomicronemia | Phase 3 | Completed | Arrowhead Pharmaceuticals | 75 | 2021-12-14 | 2026-06-05 |
| Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia ARO-APOC3, Placebo - Mixed Dyslipidemia | Phase 2 | Completed | Arrowhead Pharmaceuticals | 353 | 2021-09-28 | 2026-04-14 |
| Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS Plozasiran - Familial Chylomicronemia, High Risk Severe Hypertriglyceridemia (SHTG) | Available | Arrowhead Pharmaceuticals | 2026-03-03 |
Hypertriglyceridemia (5) · Hyperlipoproteinemia Type I (2) · Familial hyperchylomicronemia syndrome (1)
Arrowhead Pharmaceuticals (8) · Visirna Therapeutics HK Limited (1)
United States (8) · Canada (7) · Argentina (6) · Hungary (6) · Poland (6) · Australia (5) · Bulgaria (5) · Czechia (5) · Slovakia (5) · Spain (5) · Belgium (4) · Brazil (4) · China (4) · Croatia (4) · France (4)
PMID 38804517, PMID 39225259, PMID 41923352
2023 (3)